.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,399,583

« Back to Dashboard

Details for Patent: 5,399,583

Title: Method of treating skin diseases
Abstract:A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
Inventor(s): Levy; Julia G. (Vancouver, CA), Dolphin; David (Vancouver, CA), Chow; Jack J. (Vancouver, CA), Sternberg; Ethan (Vancouver, CA)
Assignee: The University of British Columbia (Vancouver, CA)
Filing Date:Jan 25, 1994
Application Number:08/187,307
Claims:1. A method for treating skin diseases in an animal which comprises topically treating an animal in need of such treatment with an effective amount of a hydro-monobenzoporphyrin (Gp) having a light absorption maximum between 670-780 nm;

wherein the Gp is selected from the group consisting of ##STR17## and mixtures thereof and the metalated and labeled forms thereof, wherein each R.sup.1 and R.sup.2 independently selected from the group consisting of carbalkoxy (2-6C), alkyl (1-6C) sulfonyl, aryl (6-10C) sulfonyl, aryl (6-10C); cyano; and --CONR.sup.5 CO-- wherein R.sup.5 is aryl (6-10C) or alkyl (1-6C);

each R.sup.3 is independently carboxyalkyl (2-6C) or a salt, amide, ester or acylhydrazone thereof, or is alkyl (1-6C); and

R.sup.4 is CHCH.sub.2, CH.sub.2 OR.sup.4', --CHO, --COOR.sup.4', CH(OR.sup.4')CH.sub.3, CH(OR.sup.4')CH.sub.2 OR.sup.4', --CH(SR.sup.4')CH.sub.3, --CH(NR.sup.4'.sub.2)CH.sub.3, --CH(CN)CH.sub.3, --CH(COOR.sup.4')CH.sub.3, --CH(halo)CH.sub.3, or --CH(halo)CH.sub.2 (halo), wherein R.sup.4' is H or alkyl (1-6C) optionally substituted with a hydrophilic substituent; or

wherein R.sup.4 is an organic group of <12C resulting from direct or indirect derivatization of vinyl; or

wherein R.sup.4 consists of 1-3 tetrapyrrole-type nuclei of the formula --L--P wherein --L-- is selected from the group consisting of ##STR18## and P is selected from the group consisting of Gp which is of the formula 1-6 but lacking R.sup.4 and conjugated through the position shown as occupied by R.sup.4 to L, and a porphyrin of the formula: ##STR19## wherein each R is independently H or lower alkyl (1-4C); wherein two of the bonds shown as unoccupied on adjacent rings are joined to R.sup.3 and one of the remaining bonds shown as unoccupied is joined to R.sup.4 and the other to L;

with the proviso that if R.sup.4 is CHCH.sub.2, both R.sup.3 cannot be carbalkoxyethyl;

and irradiating the animal with light absorbed by said Gp.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc